Journal Mobile Options
Table of Contents
Vol. 4, No. 1-2, 1998
Issue release date: March 1998
Eur Addict Res 1998;4:58–66
(DOI:10.1159/000018923)

Prevalence of Use, Abuse and Dependence of Illicit Drugs among Adolescents and Young Adults in a Community Sample

Perkonigg A. · Lieb R. · Wittchen H.-U.
Max Planck Institute of Psychiatry, Clinical Psychology and Epidemiology Unit, Munich, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Prevalence findings for 1995 of illicit drug use as well as DSM-IV abuse and dependence are reported from a representative population sample of 3,021 respondents from Munich, Germany, aged 14–24 years. Results are based on personal interviews using the M-Composite International Diagnostic Interview (M-CIDI) with its DSM-IV diagnostic algorithms. Findings indicate that more than 30% of the adolescents and young adults are or have been using one or more illicit drugs at least once in their life. Men were slightly more likely to ever use drugs and used them more frequently than women. Cannabinoids were by far the most frequently used type of drug, followed by various stimulating drugs and hallucinogens. There is also considerable polysubstance use among 14- to 24-year-olds. Criteria for DSM-IV abuse without dependence were met by 4.1% of all men and 1.8% of all women, a dependence syndrome of any type of illicit drug was diagnosed in 2.5% of the men and 1.6% of the women. Cumulative age of onset incidence analyses suggest that substance use starts early, in about one-third before the age of 16 years and continues to rise for most drugs throughout adolescence and young adulthood. Overall these findings suggest that substance use and substance disorders are more prevalent than suggested in most previous German studies.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Reuband K-H: The epidemiology of drug use in Germany: Basic data and trends; in Bühringer G, Platt JJ (eds): Drug Addiction Treatment Research. German and American Perspectives. Malabar, Krieger, 1992, pp 3–16.
  2. Bundesministerium für Gesundheit (ed): Repräsentativerhebung 1995. Schriftliche Befragung zum Gebrauch psychoaktiver Substanzen bei Erwachsenen in Deutschland. Bonn, Referat für Presse- und Öffentlichkeitsarbeit, 1996.
  3. Perkonigg A, Lieb R, Wittchen H-U: Substance use, abuse and dependence in Germany. A review of selected epidemiological data. Eur Addict Res 1998;4:8–17.
  4. Johnston LD, O’Malley PM: The recanting of earlier reported drug use by young adults. NIDA Res Monogr 1997;167:59–80.
  5. Newcomb MD, Bentler PM: Frequency of sequence of drug use: A longitudinal study from early adolescence to young adulthood. J Drug Educ 1986;16(2):101–120.
  6. Schuster P, Wittchen H-U: Ecstasy- und Halluzinogengebrauch bei Jugendlichen. Gibt es eine Zunahme? Verhaltensther Prax Forsch Perspekt 1996;6:222–233.
  7. Bundesministerium für Gesundheit (ed): Repräsentativerhebung 1994. Telefonische Befragung zum Gebrauch psychoaktiver Substanzen bei Erwachsenen in Deutschland. Bonn, Referat für Presse- und Öffentlichkeitsarbeit, 1995.
  8. Kandel DB, Yamaguchi K, Chen C: Stages of progression in drug involvement from adolescence to adulthood: Further evidence for the Gateway Theory. J Stud Alcohol 1992;53:447–457.
  9. Yu J, Williford WR: The age of alcohol onset and alcohol, cigarette, and marijuana use patterns: An analysis of drug use progression of young adults in New York. Int Addict 1992;27:1313–1323.
  10. Kraus L, Bauernfeind R, Herbst K: Hat sich das Alter des Erstkonsums illegaler Drogen verschoben? Survivalanalyse retrospektiver Querschnittsdaten 1980–1995. Z Klin Psychol 1998;27:20–29.
  11. Perkonigg A, Beloch E, Garczynski E, Nelson CB, Pfister H, Wittchen H-U: Prävalenz von Drogenmissbrauch und -abhängigkeit bei Jugendlichen und jungen Erwachsenen: Gebrauch, Diagnosen und Auftreten erster Missbrauchs- und Abhängigkeitsmerkmale. Z Klin Psychol 1997;26:247–257.
  12. Lachner G, Wittchen H-U, Perkonigg A, Holly A, Schuster P, Wunderlich U, Türk D, Garczynski E, Pfister H: Structure, content and reliability of Munich-Composite International Diagnostic Interview (M-CIDI) substance use sections. Eur Addict Res 1998;4:28–41.
  13. Lieb R, Pfister H, Wittchen H-U: Use, abuse and dependence of prescription drugs in adolescents and young adults. Eur Addict Res 1998;4:67–74.
  14. Schuster P, Lieb R, Lamertz C, Wittchen H-U: Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res 1998;4:75–82.
  15. Wittchen H-U, Perkonigg A, Lachner G, Nelson CB: Early developmental stages of psychopathology (EDSP): Objectives and design. Eur Addict Res 1998;4:18–27.
  16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, APA, 1994.
  17. Perkonigg A, Wittchen H-U, Lachner G: Wie häufig sind Substanzmissbrauch und -abhängigkeit? Ein methodenkritischer Überblick. Z Klin Psychol 1996;25:280–295.
  18. Robins LN, Regier DA (eds): Psychiatric Disorders in America. The Epidemiologic Catchment Area Study. New York, Macmillan, 1991.
  19. Warner LA, Kessler RC, Hughes M, Anthony JC, Nelson CB: Prevalence and correlates of drug use and dependence in the United States. Arch Gen Psychiatry 1995;52:219–229.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50